Biogen’s Spinraza (nusinersen) Receives NMPA (CFDA) Approval for Spinal Muscular Atrophy (SMA) Aged 6wks.

 Biogen’s Spinraza (nusinersen) Receives NMPA (CFDA) Approval for Spinal Muscular Atrophy (SMA) Aged 6wks.

Biogen’s Spinraza (nusinersen) Receives NMPA (CFDA) Approval for Spinal Muscular Atrophy (SMA) Aged 6wks.

Shots:

  • The approval is based on P-II NURTURE study results assessing Spinraza in 300 infant patients who were genetically diagnosed with SMA and had not experienced any symptoms by the time of first dose aged 6 wks.
  • The study resulted in early treatment allow 100% progressive gains in motor function, reduction in mortality in infants, 88% able to walk and safe and efficacious profile
  • Spinraza (nusinersen) is antisense oligonucleotide (ASO) developed using Ionis’ antisense technology delivered using intrathecal injection directly to CSF targeted to treat SMA and is approved in 40 countries for SMA 

Click here to read full press release/ article | Ref: Biogen | Image: INA Pharmacy

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post